Field Notes

Field Notes on Technology Disruption

Executive notes on AI, data, operating choices, corporate reinvention, and technology-led competition.

AI Is Usually Not the Product

A sharper test for deciding whether AI is the product, the interaction layer on top of a scarce asset, or simply table-stakes UX.

Read

The Great Decoupling: Building the Atomic Company

How AI agents and service-as-software are weakening the old link between revenue growth and headcount growth, and what it means to build the atomic company.

Read

The Algorithmic Apothecary

How biopharma R&D can industrialize learning with AI, closed-loop evidence, back-translation, and regulator-defensible governance.

Read

Why Your $50M Data Strategy Still Feels Like Guesswork

Why enterprise data strategies often fail to improve decision speed, and how leaders can shift from visibility to convertibility through decision contracts, low-friction discovery, and closed-loop execution.

Read

Beyond the Dashboard: Increasing Business Decision-Making Speed

Why dashboards are no longer enough, and how leaders can reduce decision latency by moving from passive visibility to triggers, diagnostics, guardrails, and action.

Read

The Frozen Middle Is Missing a Control Plane

Why the frozen middle is less about resistance to change and more about missing control-plane architecture for high-velocity agentic work.

Read

Your Data Is Not a Moat. Your Feedback Loops Are.

Why accumulating data is not enough in the age of synthetic data, and how executives can build durable AI advantage through workflow-embedded feedback loops.

Read

Your AI Pilot Is Doomed. You Need an AI Operating System.

Why AI pilots stall inside large enterprises, and what it takes to connect outcomes, funding, product teams, data products, governance, adoption, and learning.

Read

Why Incumbents Lose Speed: The Three Clocks Problem

Why incumbents lose speed when product, risk, and finance run on different clocks, and how to make speed safe and capital more agile.

Read

Scaling Impact from Pharma Commercial Analytics

How commercial pharma analytics can drive better decisions, faster action, lower cost, stronger measurement, scalable adoption, and more useful work for teams.

Read

Something Is Happening

What it takes to capture value from AI and generative AI at scale: sharper use cases, stronger data, better talent, and leadership discipline beyond pilots.

Read

経営者の視点から見た生成AI

海外事例をもとに、生成AIがビジネスにもたらす価値、スケーラビリティの難しさ、経営者が取るべき実践的な打ち手を整理する。

Read

Is AI Eating the World?

Part one of a three-part perspective on who is making money from AI, whether AI will eat the world like software did, and where value may accrue across data, software, cloud, and models.

Read

Is Not Pursuing AI Like Burning Money?

Where companies underinvest in AI, where the value is real, and how leaders can move from experiments to scaled returns.

Read

Innovator’s Dilemma on Steroids?

Three questions for judging whether a technology shift will actually reshape an industry, and whether incumbents can still win.

Read